Akero Therapeutics, Inc. (AKRO) News
Filter AKRO News Items
AKRO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AKRO News Highlights
- For AKRO, its 30 day story count is now at 3.
- Over the past 13 days, the trend for AKRO's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DEC, PATH and PRE are the most mentioned tickers in articles about AKRO.
Latest AKRO News From Around the Web
Below are the latest news stories about AKERO THERAPEUTICS INC that investors may wish to consider to help them evaluate AKRO as an investment opportunity.
Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY ProgramWeek 96 Phase 2b HARMONY Results for Treatment of Patients with Pre-Cirrhotic NASH/MASH (F2-F3) to be Reported in March 2024 End-of-Phase 2 FDA Meeting Scheduled for the first quarter of 2024 to Review Phase 3 Study and Regulatory Path for Treatment of NASH/MASH Patients with Compensated Cirrhosis (F4) SOUTH SAN FRANCISCO, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious me |
Insider Sell Alert: Akero Therapeutics Inc's President and CEO Andrew Cheng Disposes of 26,978 ...In a notable insider trading event, President and CEO Andrew Cheng of Akero Therapeutics Inc (NASDAQ:AKRO) sold 26,978 shares of the company on December 11, 2023. |
12 Most Promising Stocks to Buy According to Hedge FundsIn this article, we will take a look at the 12 most promising stocks to buy according to hedge funds. To see more such companies, go directly to 5 Most Promising Stocks to Buy According to Hedge Funds. Analysts and financial institutions are starting to release their 2024 market outlook reports and predictions and you […] |
Akero Therapeutics Inc (AKRO) Reports Q3 2023 Financial ResultsAdvances in NASH Treatment Candidate Efruxifermin (EFX) with Phase 3 Trials on the Horizon |
Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update-- Phase 3 SYNCHRONY studies actively screening and on track to begin enrolling by the end of 2023 -- SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported third quarter financial results for the period ending September 30, 2023 and provided business updates. “We continue to be encouraged b |
Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD’s The Liver Meeting® 2023Phase 2b SYMMETRY 36-week data, including new subgroup analysis, showed that EFX is active in patients with advanced cirrhosis and support continued development of EFX for treatment of cirrhosis due to NASH/MASH 22% and 10% of patients with more advanced cirrhosis in the 50mg and 28mg dose groups, respectively, had at least a one-stage improvement in fibrosis without worsening of NASH, over 7 and 3 times, respectively, the placebo rate of 3% Additional analyses from the HARMONY and SYMMETRY stud |
Akero Therapeutics to Present at Upcoming Healthcare Conferences in NovemberSOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced management will present at the following investor conferences this month: Jefferies London Healthcare Conference: Fireside chat on Wednesday, November 15 at 5:00 p.m. GMTEvercore ISI HealthCONx Conference: Fireside chat on Wednesday, Nov |
Akero Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Virtual Investor ConferenceSOUTH SAN FRANCISCO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced management will present virtually at the H.C. Wainwright 7th Annual NASH Conference on Tuesday, October 24, 2023, at 12:00 p.m. E.T. A live webcast of the fireside chat will be available through the investor relations section of the Comp |
Why Akero Therapeutics Shares Are Slumping This WeekShares of Akero Therapeutics (NASDAQ: AKRO) were down more than 70% for the week as of Thursday's close, according to data provided by S&P Global Market Intelligence. The clinical-stage biotech company saw its shares slump after it announced on Tuesday that efruxifermin, its lead pipeline candidate, missed its primary endpoint in a phase 2b study to treat nonalcoholic steatohepatitis (NASH). According to the company, patients with cirrhosis (scarring of the liver) due to NASH are unlikely to live longer than five years after diagnosis unless they receive a liver transplant. |
Biotech Stock Roundup: BMY Grabs MRTX, AKRO Down on Study Data, ALNY Faces SetbackAcquisition and pipeline updates from Bristol Myers (BMY) and Akero Therapeutics (AKRO) are in focus in the biotech sector. |